Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Lys-MDA

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Lys-MDA
Clinical data
Other namesN-(L-Lysinamidyl)-MDA;N-(L-Lysinamidyl)-3,4-methylenedioxyamphetamine
Routes of
administration
Oral[1]
Drug classSerotonin–norepinephrine–dopamine releasing agent;Serotonin5-HT2 receptoragonist;Entactogen;Empathogen;Serotonergic psychedelic;Hallucinogen;Stimulant
ATC code
  • None
Pharmacokinetic data
MetabolitesMDA[1]
Identifiers
  • (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
CAS Number
Chemical and physical data
FormulaC16H25N3O3
Molar mass307.394 g·mol−1
3D model (JSmol)
  • CC(Cc2ccc1OCOc1c2)NC(=O)C(N)CCCCN
  • InChI=1S/C16H25N3O3/c1-11(19-16(20)13(18)4-2-3-7-17)8-12-5-6-14-15(9-12)22-10-21-14/h5-6,9,11,13H,2-4,7-8,10,17-18H2,1H3,(H,19,20)/t11?,13-/m0/s1
  • Key:ZUWUZALZPUJLCD-YUZLPWPTSA-N

Lys-MDA, orlysine-MDA, also known asN-(L-lysinamidyl)-MDA, is anentactogen of thephenethylamine,amphetamine, andMDxx families withentactogenic effects, which acts as aprodrug forMDA with a somewhat sloweronset of effects and longerduration of action.[1] Lys-MDA, along with the related derivativeLys-MDMA, are in early stage humanclinical trials as potential treatments fortreatment-resistant depression andpost-traumatic stress disorder. NewMDMA prodrugs are in the development phase atMiHKAL GmbH in Switzerland.[2][3][4][5] Aphase 1clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.[6] The trial results, which includedpharmacodynamic andpharmacokinetic findings, was published in September 2025.[1]

Interactions

[edit]
See also:MDMA § Interactions,Psychedelic drug § Interactions,Trip killer § Serotonergic psychedelic antidotes,Trip killer § Antidotes of other hallucinogens, andMDMA/citalopram

See also

[edit]

References

[edit]
  1. ^abcdStraumann I, Vizeli P, Avedisian I, Erne L, Noorshams D, Vukalovic I, Eckert A, Luethi D, Rudin D, Liechti ME (September 2025)."Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants".Neuropsychopharmacology.doi:10.1038/s41386-025-02248-3.PMID 40999236.
  2. ^Buntz B (21 September 2022)."MindMed announces Phase 1 study of MDMA-like substances".Drug Discovery and Development.
  3. ^"MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances".Biospace.com. 20 September 2022.
  4. ^WO 2022/053696, Grill M, "Novel Safrylamine derivatives having prodrug properties.", published 17 March 2022, assigned to Compass Pathfinder Limited. 
  5. ^WO 2023/283373, Clark S, Duncton MA, "Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof", published 12 January 2023, assigned to Terran Biosciences Inc. 
  6. ^"ClinicalTrials.gov".ClinicalTrials.gov. 13 August 2024. Retrieved13 November 2024.

External links

[edit]
Phenethylamines
Non-ring-extended
Benzodioxoles
(methylenedioxy- or MDxx)
Benzodioxines
(ethylenedioxy-)
Benzofurans
Dihydrobenzofurans
Benzothiophenes
Benzothiazoles
Benzoxathioles
Indanes
Indoles
Naphthalenes
Tetralins
Others
Cyclized
phenethylamines
2-Aminoindanes
1-Aminomethylindanes
2-Aminotetralins
Aminorexes
Tryptamines
α-Alkyltryptamines
Others
Benzofurans
Benzothiophenes
Indolizines
Isotryptamines
Others
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lys-MDA&oldid=1323679525"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp